BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 27339594)

  • 1. Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
    Zeng J; Lv L; Mei ZC
    Clin Res Hepatol Gastroenterol; 2016 Dec; 40(6):688-697. PubMed ID: 27339594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Li L; Zhao W; Wang M; Hu J; Wang E; Zhao Y; Liu L
    BMC Gastroenterol; 2018 Sep; 18(1):138. PubMed ID: 30180810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
    Zhang L; Hu P; Chen X; Bie P
    PLoS One; 2014; 9(6):e100305. PubMed ID: 24945380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Yang M; Yuan JQ; Bai M; Han GH
    Mol Biol Rep; 2014 Oct; 41(10):6575-82. PubMed ID: 25091939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
    Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
    Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
    J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
    Fu QH; Zhang Q; Bai XL; Hu QD; Su W; Chen YW; Su RG; Liang TB
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1429-40. PubMed ID: 24770582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
    Zhao Y; Li H; Bai W; Liu J; Lv W; Sahu S; Guan S; Qin X; Wang W; Ren W; Mu W; Guo W; Gu S; Ma Y; Yin Z; Guo W; Wang W; Wang Y; Duran R; Fan D; Zhang Z; Han G
    Int J Cancer; 2016 Aug; 139(4):928-37. PubMed ID: 27038145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
    Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
    J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
    Huang Y; Chen B; Liu N; Li N; Dao H; Chen W; Yang J
    Int J Clin Pharmacol Ther; 2017 Jun; 55(6):498-508. PubMed ID: 28157070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
    Wang G; Liu Y; Zhou SF; Qiu P; Xu L; Wen P; Wen J; Xiao X
    Hepatol Int; 2016 May; 10(3):501-10. PubMed ID: 26856326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
    Liu L; Chen H; Wang M; Zhao Y; Cai G; Qi X; Han G
    PLoS One; 2014; 9(3):e91124. PubMed ID: 24651044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
    Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
    BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
    Hu H; Duan Z; Long X; Hertzanu Y; Shi H; Liu S; Yang Z
    PLoS One; 2014; 9(5):e96620. PubMed ID: 24817002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
    Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
    Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
    Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
    PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
    Wu FX; Chen J; Bai T; Zhu SL; Yang TB; Qi LN; Zou L; Li ZH; Ye JZ; Li LQ
    BMC Cancer; 2017 Sep; 17(1):645. PubMed ID: 28899349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
    Pan T; Li XS; Xie QK; Wang JP; Li W; Wu PH; Zhao M
    Clin Radiol; 2014 Dec; 69(12):e553-61. PubMed ID: 25304928
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
    Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O
    Oncology; 2014; 87(6):330-41. PubMed ID: 25227534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
    Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
    J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.